


## Supplementary information

eFigure S1. Personalized Treatment Interval Phase Dosing Criteria



BCVA = best-corrected visual acuity; CST = central subfield thickness; Q8W = every 8 weeks; nAMD, neovascular age-related macular degeneration; Q16W = every 16 weeks.

\*Where stability is defined as a change of CST of less than 30  $\mu\text{m}$ .

†Compared with the average of the last 2 study drug dosing visits.

‡Compared with the lowest on-study drug dosing visit measurement.

§Change in BCVA should be attributable to nAMD disease activity (as determined by the investigator).

||Compared with the highest on-study drug dosing visit measurement.

¶Refers to macular hemorrhage owing to nAMD activity (as determined by investigator).

\*\*Patients whose treatment interval is reduced by 8 weeks, from Q16W to Q8W, will not be allowed to return to a Q16W interval during the study.